Amalgamated Bank Arrowhead Pharmaceuticals, Inc. Transaction History

Amalgamated Bank

  • $13.6 Billion
  • Q3 2025

A detailed history of Amalgamated Bank transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 39,413 shares of ARWR stock, worth $1.49 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
39,413
Previous 35,543 10.89%
Holding current value
$1.49 Million
Previous $561,000 142.25%
% of portfolio
0.01%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 29, 2025
BUY
$14.71 - $34.49 $56,927 - $133,476
3,870 Added 10.89%
39,413 $1.36 Million
Q2 2025

Aug 04, 2025
SELL
$9.99 - $16.97 $2,007 - $3,410
-201 Reduced 0.56%
35,543 $561,000
Q1 2025

Apr 25, 2025
SELL
$12.74 - $21.53 $267,259 - $451,656
-20,978 Reduced 36.98%
35,744 $455,000
Q4 2024

Feb 04, 2025
BUY
$17.7 - $26.34 $34,638 - $51,547
1,957 Added 3.57%
56,722 $1.07 Million
Q3 2024

Oct 30, 2024
SELL
$19.36 - $29.54 $102,356 - $156,177
-5,287 Reduced 8.8%
54,765 $1.06 Million
Q2 2024

Aug 12, 2024
SELL
$21.87 - $28.24 $100,864 - $130,242
-4,612 Reduced 7.13%
60,052 $1.56 Million
Q1 2024

Apr 23, 2024
SELL
$27.21 - $39.48 $53,794 - $78,051
-1,977 Reduced 2.97%
64,664 $1.85 Million
Q4 2023

Feb 06, 2024
BUY
$21.2 - $31.03 $2,607 - $3,816
123 Added 0.18%
66,641 $2.04 Million
Q3 2023

Nov 08, 2023
SELL
$26.2 - $36.08 $71,709 - $98,750
-2,737 Reduced 3.95%
66,518 $1.79 Million
Q2 2023

Aug 11, 2023
SELL
$25.16 - $41.38 $61,516 - $101,174
-2,445 Reduced 3.41%
69,255 $2.47 Million
Q1 2023

May 02, 2023
SELL
$23.68 - $38.51 $63,651 - $103,514
-2,688 Reduced 3.61%
71,700 $1.82 Million
Q4 2022

Feb 10, 2023
BUY
$28.0 - $40.56 $36,596 - $53,011
1,307 Added 1.79%
74,388 $3.02 Million
Q3 2022

Nov 09, 2022
BUY
$29.63 - $48.31 $51,082 - $83,286
1,724 Added 2.42%
73,081 $2.42 Million
Q2 2022

Aug 15, 2022
BUY
$27.79 - $50.61 $9,670 - $17,612
348 Added 0.49%
71,357 $2.51 Million
Q1 2022

Jun 30, 2022
SELL
$39.62 - $69.97 $108,717 - $191,997
-2,744 Reduced 3.72%
71,009 $3.27 Million
Q4 2021

Feb 15, 2022
BUY
$58.09 - $82.51 $16,497 - $23,432
284 Added 0.39%
73,753 $4.89 Million
Q3 2021

Oct 29, 2021
SELL
$58.38 - $84.96 $449,292 - $653,852
-7,696 Reduced 9.48%
73,469 $4.59 Million
Q2 2021

Aug 16, 2021
BUY
$62.15 - $90.32 $4.08 Million - $5.93 Million
65,699 Added 424.8%
81,165 $6.72 Million
Q1 2021

May 13, 2021
SELL
$61.35 - $90.47 $68,650 - $101,235
-1,119 Reduced 6.75%
15,466 $1.03 Million
Q4 2020

Feb 12, 2021
BUY
$43.82 - $85.37 $7,011 - $13,659
160 Added 0.97%
16,585 $1.27 Million
Q3 2020

Oct 30, 2020
SELL
$33.21 - $51.27 $17,933 - $27,685
-540 Reduced 3.18%
16,425 $707,000
Q2 2020

Aug 10, 2020
SELL
$26.12 - $43.27 $32,728 - $54,217
-1,253 Reduced 6.88%
16,965 $733,000
Q1 2020

May 13, 2020
BUY
$20.56 - $63.12 $5,633 - $17,294
274 Added 1.53%
18,218 $524,000
Q4 2019

Feb 13, 2020
BUY
$28.14 - $73.01 $15,195 - $39,425
540 Added 3.1%
17,944 $1.14 Million
Q3 2019

Nov 13, 2019
SELL
$26.26 - $34.86 $7,037 - $9,342
-268 Reduced 1.52%
17,404 $490,000
Q2 2019

Aug 14, 2019
BUY
$17.43 - $28.82 $73,694 - $121,850
4,228 Added 31.45%
17,672 $468,000
Q1 2019

May 15, 2019
BUY
$12.05 - $20.18 $7,712 - $12,915
640 Added 5.0%
13,444 $247,000
Q4 2018

Feb 15, 2019
BUY
$10.74 - $19.7 $137,514 - $252,238
12,804 New
12,804 $159,000
Q3 2018

Nov 14, 2018
SELL
$14.0 - $20.3 $185,990 - $269,685
-13,285 Closed
0 $0
Q2 2018

Jul 18, 2018
BUY
$6.37 - $14.02 $84,625 - $186,255
13,285 New
13,285 $181,000

Others Institutions Holding ARWR

# of Institutions
332
Shares Held
99.7M
Call Options Held
444K
Put Options Held
568K
View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

ARWR Quotes by TradingView
  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $4.01B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email